We acquire, develop and license innovative drugs to treat pandemic infections. We have expanded to develop a broader portfolio of new therapies to meet the rising burden of critical priority infectious disease. Based at Alderley Park in the North West of England, our work addresses unmet patient needs and will bring new portfolio of drugs into clinical trials to treat patients suffering from life-threatening infections.
Breaking News
Infex agrees partnership with Colibri Scientific to provide services for RESP-X program
Infex Therapeutics has today announced a deal with Colibri Scientific, to provide logistics and sample operational services for Infex’s RESP-X program.
Infex scientists achieve breakthrough with potential new drug for Omicron and new coronavirus strains
One of the UK’s leading infectious disease biotech companies has announced a breakthrough in laboratory trials of a new drug to treat COVID-19 and new variants of the disease, such as the Omicron…
Budget’s R&D investment increase must propel action on AMR, says Dr Peter Jackson of Infex Therapeutics
“The announcement today that the government is increasing public R&D investment to record levels to cement the UK as a global science and technology superpower is hugely encouraging news, and…
Latest News
Infex agrees partnership with Colibri Scientific to provide services for RESP-X program
Infex Therapeutics has today announced a deal with Colibri Scientific, to provide…
Infex scientists achieve breakthrough with potential new drug for Omicron and new coronavirus strains
One of the UK’s leading infectious disease biotech companies has announced a breakthrough…
Budget’s R&D investment increase must propel action on AMR, says Dr Peter Jackson of Infex Therapeutics
“The announcement today that the government is increasing public R&D investment to record…
Infex Therapeutics sharpens Covid focus with new CRUK Newcastle partnership
Infex Therapeutics is pressing ahead with a major development of its pandemic resilience…
Tackling underlying respiratory conditions for this pandemic and next
During the COVID-19 pandemic, one of the many phrases that has become irreversibly etched…
Infex partners with Alderley Analytical to provide PK and ADA analysis for RESP-X program
Infex Therapeutics has today announced a deal with Alderley Analytical, to support PK and…
Deals agreed as Infex’s resistance bypass drug program heads for clinic
Infex Therapeutics has appointed Pharmaron to help progress its MET-X program which…
Infex focuses on pandemic preparedness with Covid patent
Infex Therapeutics has filed for a UK patent for a novel therapy designed to tackle all…